MoonLake Immunotherapeutics (MLTX)
USD 37.85
(2.38%)
USD 37.85
(2.38%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | 13.15 Thousand | 12.35 Thousand | 4971.00 | - |
| Gross Profit | -13.15 Thousand | -12.35 Thousand | -4971.00 | - |
| Operating Expenses | 54.12 Million | 65.06 Million | 53.57 Million | 105.75 Thousand |
| Selling, General and Administrative Expenses | 22.32 Million | 23.01 Million | 18.04 Million | 105.75 Thousand |
| Research and Development Expenses | 31.8 Million | 42.04 Million | 35.52 Million | - |
| Other Expenses | - | 591.73 Thousand | - | - |
| Cost and Expenses | 54.12 Million | 65.06 Million | 53.57 Million | 105.75 Thousand |
| Operating Income | -54.12 Million | -65.06 Million | -53.57 Million | -105.76 Thousand |
| Interest Expense | - | - | - | - |
| Income Tax Expense | 94.38 Thousand | 36.36 Thousand | 4755.00 | -206.29 Thousand |
| Earnings before Tax | -43.98 Million | -64.46 Million | -53.63 Million | -90.83 Thousand |
| Net Income | -36 Million | -64.5 Million | -53.64 Million | -90.83 Thousand |
| Earnings Per Share Basic | -0.73 | -2.20 | -6.84 | -0.01 |
| Earnings Per Share Diluted | -0.73 | -2.20 | -6.84 | -0.01 |
| Weighted Average Shares Outstanding | 49.12 Million | 29.36 Million | 7.84 Million | 14.8 Million |
| Weighted Average Shares Outstanding (Diluted) | 49.12 Million | 29.36 Million | 7.84 Million | 14.8 Million |
| Gross Margin | - | - | - | - |
| EBIT Margin | - | - | - | - |
| Profit Margin | - | - | - | - |
| EBITDA | -54.1 Million | -65.04 Million | -53.63 Million | -90.83 Thousand |
| Earnings Before Tax Margin | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 19.73 Thousand | - | - | - |
| Cost of Revenue | 28.11 Thousand | 22.81 Thousand | 3289.00 | 13.15 Thousand | 3290.00 | 3289.00 |
| Gross Profit | -28.11 Thousand | -22.81 Thousand | 16.44 Thousand | -13.15 Thousand | -3290.00 | -3289.00 |
| Operating Expenses | 30.55 Million | 19.79 Million | 15.02 Million | 54.1 Million | 12.97 Million | 13.18 Million |
| Selling, General and Administrative Expenses | 6.91 Million | 6.8 Million | 6.93 Million | - | 5.39 Million | 4.48 Million |
| Research and Development Expenses | 23.63 Million | 12.99 Million | 8.09 Million | - | 7.58 Million | 8.7 Million |
| Other Expenses | 5.93 Million | 5.91 Million | 7.18 Million | - | 1.38 Million | 842.65 Thousand |
| Cost and Expenses | 30.57 Million | 19.82 Million | 15.02 Million | 54.12 Million | 12.97 Million | 13.18 Million |
| Operating Income | -30.57 Million | -19.82 Million | -15.02 Million | -54.12 Million | -12.97 Million | -13.18 Million |
| Interest Expense | - | - | 3.93 Million | - | - | - |
| Income Tax Expense | 78.7 Thousand | 70.25 Thousand | 44.3 Thousand | 94.38 Thousand | 28.92 Thousand | 10.14 Thousand |
| Earnings before Tax | -24.68 Million | -13.9 Million | -7.84 Million | -43.98 Million | -11.59 Million | -12.34 Million |
| Net Income | -24.26 Million | -13.67 Million | -7.43 Million | -36 Million | -9.42 Million | -10.13 Million |
| Earnings Per Share Basic | -0.39 | -0.22 | -0.12 | - | -0.18 | -0.23 |
| Earnings Per Share Diluted | -0.39 | -0.22 | -0.12 | - | -0.18 | -0.23 |
| Weighted Average Shares Outstanding | 62.87 Million | 62.63 Million | 59.91 Million | 49.12 Million | 53.51 Million | 43.71 Million |
| Weighted Average Shares Outstanding (Diluted) | 62.87 Million | 62.63 Million | 59.91 Million | 49.12 Million | 53.51 Million | 43.71 Million |
| Gross Margin | - | - | 0.83 | - | - | - |
| EBIT Margin | - | - | -761.25 | - | - | - |
| Profit Margin | - | - | -376.79 | - | - | - |
| EBITDA | -30.55 Million | -19.79 Million | -15.02 Million | - | -12.97 Million | -13.18 Million |
| Earnings Before Tax Margin | - | - | -761.42 | - | - | - |
7723
AMSWA
GLITTEKG
NINTF
SGR-UN
CCOI